Anzeige
Mehr »
Login
Montag, 06.05.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
+56,25% in 5 Tagen: Genialer Schachzug - diese Übernahme verändert alles
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
28 Leser
Artikel bewerten:
(0)

Apollo Endosurgery Completes Acquisition of Allergan Inc.'s Obesity Intervention Division

AUSTIN, Texas, Dec. 2, 2013 /PRNewswire/ -- Apollo Endosurgery, Inc., a leading developer of medical devices for endoscopic surgical procedures, today announced the completion of the acquisition of the obesity intervention division of Allergan, Inc., which manufactures and sells weight loss solutions comprised of the LAP-BAND® adjustable gastric banding system and the ORBERA' intra-gastric balloon system.

"With worldwide obesity numbers reaching epidemic levels, the acquisition of the LAP-BAND® and ORBERA' technologies places Apollo Endosurgery in a leadership position to provide surgeons and patients with innovative and less invasive solutions in the fight against obesity," said Dennis McWilliams, President and CEO of Apollo Endosurgery. "By expanding both our product portfolio and adding talent to our team, this acquisition will be a catalyst for growth as we continue to advance technologies in the fields of bariatric and minimally invasive surgery."

About the Acquisition
Apollo announced the acquisition on October 29, 2013, for a purchase price of up to $110 million. This total includes an upfront cash payment of $75 million, a minority equity interest in Apollo by Allergan of $15 million, and up to $20million in additional contingent consideration to be paid upon achievement of certain regulatory and sales milestones.

Piper Jaffray & Co. served as exclusive financial advisor and Cooley LLP served as legal counsel to Apollo Endosurgery in connection with the transaction. Current Apollo investors PTV Sciences, H.I.G. BioVentures, Remeditex Ventures, Novo A/S and CPMG, Inc. provided the equity financing of the acquisition. Debt financing was led by Oxford Finance LLC, who was joined by MidCap Financial, LLC and EastWest Financial Services.

About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is dedicated to revolutionizing patient care through the adoption of less invasive bariatric and endoscopic surgical solutions. Apollo Endosurgery was cofounded with the Apollo Group, a unique collaboration of physicians from the Mayo Clinic, Johns Hopkins University, Medical University of South Carolina, the University of Texas Medical Branch and the Chinese University of Hong Kong. This collaboration developed a broad portfolio of patents in the field of endoscopic surgery that became the foundation of Apollo Endosurgery. For more information regarding Apollo Endosurgery, go to www.apolloendo.com.

Apollo Endosurgery, LAP-BAND, and ORBERA are trademarks of Apollo Endosurgery, Inc.

SOURCE Apollo Endosurgery, Inc.

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.